BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24853169)

  • 1. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults.
    Altcheh J; Moscatelli G; Mastrantonio G; Moroni S; Giglio N; Marson ME; Ballering G; Bisio M; Koren G; García-Bournissen F
    PLoS Negl Trop Dis; 2014 May; 8(5):e2907. PubMed ID: 24853169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice.
    Perin L; Moreira da Silva R; Fonseca KD; Cardoso JM; Mathias FA; Reis LE; Molina I; Correa-Oliveira R; Vieira PM; Carneiro CM
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole.
    Sperandio da Silva GM; Mediano MF; Alvarenga Americano do Brasil PE; da Costa Chambela M; da Silva JA; de Sousa AS; Xavier SS; Rodrigues da Costa A; Magalhães Saraiva R; Hasslocher-Moreno AM
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6371-7. PubMed ID: 25114135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil.
    Gontijo MKCL; Arruda HMBDS; Noronha EF; Toledo MI
    Rev Soc Bras Med Trop; 2020; 53():e20190150. PubMed ID: 31994658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial.
    Molina-Morant D; Fernández ML; Bosch-Nicolau P; Sulleiro E; Bangher M; Salvador F; Sanchez-Montalva A; Ribeiro ALP; de Paula AMB; Eloi S; Correa-Oliveira R; Villar JC; Sosa-Estani S; Molina I
    Trials; 2020 Apr; 21(1):328. PubMed ID: 32293523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural Bolivia.
    Tornheim JA; Lozano Beltran DF; Gilman RH; Castellon M; Solano Mercado MA; Sullca W; Torrico F; Bern C
    PLoS Negl Trop Dis; 2013; 7(9):e2407. PubMed ID: 24069472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe immune thrombocytopaenia in a patient taking benznidazole for chronic Chagas disease.
    Crespillo-Andújar C; Calbacho Robles M; Norman FF; Pérez-Molina JA
    BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29588298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of benznidazole in adult patients with Chagas disease.
    Soy D; Aldasoro E; Guerrero L; Posada E; Serret N; Mejía T; Urbina JA; Gascón J
    Antimicrob Agents Chemother; 2015; 59(6):3342-9. PubMed ID: 25824212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.
    de Andrade AL; Zicker F; de Oliveira RM; Almeida Silva S; Luquetti A; Travassos LR; Almeida IC; de Andrade SS; de Andrade JG; Martelli CM
    Lancet; 1996 Nov; 348(9039):1407-13. PubMed ID: 8937280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.
    Morillo CA; Marin-Neto JA; Avezum A; Sosa-Estani S; Rassi A; Rosas F; Villena E; Quiroz R; Bonilla R; Britto C; Guhl F; Velazquez E; Bonilla L; Meeks B; Rao-Melacini P; Pogue J; Mattos A; Lazdins J; Rassi A; Connolly SJ; Yusuf S;
    N Engl J Med; 2015 Oct; 373(14):1295-306. PubMed ID: 26323937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease.
    Sosa Estani S; Segura EL; Ruiz AM; Velazquez E; Porcel BM; Yampotis C
    Am J Trop Med Hyg; 1998 Oct; 59(4):526-9. PubMed ID: 9790423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Benznidazole in Healthy Volunteers and Implications in Future Clinical Trials.
    Molina I; Salvador F; Sánchez-Montalvá A; Artaza MA; Moreno R; Perin L; Esquisabel A; Pinto L; Pedraz JL
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trypanocidal treatment of Chagas disease.
    Pérez-Molina JA; Crespillo-Andújar C; Bosch-Nicolau P; Molina I
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Jun; ():. PubMed ID: 32527494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicines against Chagas disease: a critical review.
    Morilla MJ; Ghosal K; Romero EL
    Beilstein J Nanotechnol; 2024; 15():333-349. PubMed ID: 38590427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials for Chagas disease: etiological and pathophysiological treatment.
    Gonzaga BMS; Ferreira RR; Coelho LL; Carvalho ACC; Garzoni LR; Araujo-Jorge TC
    Front Microbiol; 2023; 14():1295017. PubMed ID: 38188583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation.
    Altcheh J; Moscatelli G; Caruso M; Moroni S; Bisio M; Miranda MR; Monla C; Vaina M; Valdez M; Moran L; Ramirez T; Patiño OL; Riarte A; Gonzalez N; Fernandes J; Alves F; Ribeiro I; Garcia-Bournissen F
    PLoS Negl Trop Dis; 2023 May; 17(5):e0010850. PubMed ID: 37256863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further Investigations of Nitroheterocyclic Compounds as Potential Antikinetoplastid Drug Candidates.
    García-Estrada C; Pérez-Pertejo Y; Domínguez-Asenjo B; Holanda VN; Murugesan S; Martínez-Valladares M; Balaña-Fouce R; Reguera RM
    Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189384
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.